文献速递胸部肿瘤

阿替利珠单抗单药治疗转移性非小细胞肺癌:I期研究最终结果

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
PubMed 文献 · Eur J Cancer · 2018-08-01

整体客观缓解率23%,PD-L1高表达亚组ORR达50%,中位缓解持续时间16.4个月,3年生存率28%。单药耐受良好,疗效随基线PD-L1表达升高而改善。

要点

  • 经治NSCLC患者中阿替利珠单抗单药ORR为23%,中位缓解持续时间16.4个月。
  • PD-L1 TC3或IC3亚组ORR达50%,TC0且IC0亚组仅11%。
  • III/IV级治疗相关不良事件发生率11%,以疲乏、呼吸困难等为主。

核心结论

  • 阿替利珠单抗单药在经治转移性NSCLC中耐受良好,具有持久缓解和长期生存获益。
  • 基线PD-L1表达越高,缓解率和生存率改善越明显。

研究设计与样本

  • 98%患者既往接受过系统性治疗,基线PD-L1表达采用VENTANA SP142免疫组化检测肿瘤细胞和肿瘤浸润免疫细胞。

主要发现

  • 整体ORR为23%(95%CI 14%-33%),中位缓解持续时间16.4个月(范围7.2-53.4+)。
  • TC3或IC3、TC2/3或IC2/3、TC1/2/3或IC1/2/3、TC0且IC0亚组ORR分别为50%(28%-72%)、33%(20%-48%)、29%(18%-41%)、11%(1%-35%)。
  • 1年、2年、3年生存率分别为63%(53%-73%)、37%(26%-47%)、28%(18%-38%)。
  • III/IV级治疗相关不良事件见于10例(11%),>10%的全级不良事件为疲乏、恶心和食欲下降。

关键数值与推荐

  • PD-L1 TC3或IC3亚组ORR 50%(95%CI 28%-72%),TC2/3或IC2/3亚组33%(20%-48%)。
  • TC0且IC0亚组ORR 11%(95%CI 1%-35%),全人群ORR 23%(14%-33%)。
  • III/IV级治疗相关不良事件发生率11%,>2%的III/IV级事件包括疲乏、呼吸困难、低钠血症和缺氧。

临床怎么用

  • 经治转移性NSCLC可考虑阿替利珠单抗单药治疗,尤其PD-L1高表达患者可能获益更明显。
  • 治疗期间需监测疲乏、呼吸困难、低钠血症和缺氧等不良事件。

局限性

  • 患者接受多种剂量(1-20 mg/kg或1200 mg固定剂量),非随机对照设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Atezolizumab, an anti-programmed death-ligand 1 (PD-L1) antibody, inhibits PD-L1:PD-1 and PD-L1:B7.1 interactions, restoring anticancer immunity. Here, we report final analyses from the non-small-cell lung cancer (NSCLC) cohort of the first atezolizumab phase I study. METHODS: Patients with NSCLC received atezolizumab 1-20 mg/kg or 1200 mg intravenously every 3 weeks. Baseline PD-L1 expression on tumour cells (TCs) and tumour-infiltrating immune cells (ICs) was assessed (VENTANA SP142 immunohistochemistry assay). Exploratory subgroup analyses investigated responses by baseline PD-L1 expression and oncogenic mutational status. RESULTS: Eighty-nine patients, 98% of whom had received previous systemic therapy, were evaluable for safety and antitumour activity. Atezolizumab was well tolerated, with grade III/IV treatment-related adverse events (TRAEs) observed in 10 patients (11%). All-grade TRAEs occurring in >10% of patients were fatigue, nausea and decreased appetite; grade III/IV TRAEs occurring in >2% of patients were fatigue, dyspnoea, hyponatremia and hypoxia. One patient died from treatment-unrelated pneumonia. Objective response rate (ORR) was 50% (95% confidence interval [CI], 28%-72%), 33% (20%-48%), 29% (18%-41%) and 11% (1%-35%) for the TC3 or IC3, TC2/3 or IC2/3, TC1/2/3 or IC1/2/3 and TC0 and IC0 subgroups, respectively. All-patient ORR was 23% (95% CI, 14%-33%). Median duration of response was 16.4 months (range, 7.2-53.4+). One-, 2-, and 3-year survival rates were 63% (95% CI, 53%-73%), 37% (26%-47%) and 28% (18%-38%), respectively. CONCLUSIONS: Single-agent atezolizumab was well tolerated with long-term clinical benefits, including durable responses and survival, in pretreated NSCLC. Improved responses and survival rates were seen with increasing baseline PD-L1 expression. CLINICALTRIALS. GOV IDENTIFIER: NCT01375842.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Horn L, Gettinger SN, Gordon MS, et al. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018. PMID: 30077125. doi:10.1016/j.ejca.2018.06.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。